• Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa
  • Imagem ilustrativa

Programação » Sessão de Encontro com Autor

Código: P 107
Apresentação: Oral, segunda opção Pôster
Área Técnica: Uveites / AIDS
Categoria / Classificação: Oftalmologia Clinica
Região onde foi realizada a pesquisa: Sudeste

INSTITUIÇÃO ONDE FOI REALIZADO O TRABALHO:

CONEP:

AUTOR PRINCIPAL:

CO-AUTOR(ES):

TÍTULO:
INTRAVITREAL BEVACIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION IN VOGT-KOYANAGI-HARADA DISEASE

OBJETIVO:
Choroidal neovascularization (CNV) is a rare but devastating complication in Vogt-Koyanagi-Harada (VKH) disease, associated with poor visual prognosis and no standard treatment. This prospective study assesses the effectiveness of intravitreal (IV) bevacizumab associated to systemic immunosuppressants in the treatment of CNV in VKHD.

MÉTODO:
Active CNV was defined by angiography and optical coherence tomography findings. Anterior chamber cells and/or optic disc leakage in fluorescein angiography characterized disease activity. Each patient underwent a complete clinical exam, including best corrected visual acuity (VA) measurement using Snellen charts, OCT and FA, which were performed in Spectralis HRA-OCT. Treatment protocol consisted of three monthly IV bevacizumab injections as a loading dose; if intra/subretinal fluid (IRF) persisted, further injections were proceeded besides increment in systemic immunosuppression. Main outcome measures were improvement of VA, decrease in central foveal thickness as measured by OCT and absence of intra/subretinal fluid at six months endpoint.

RESULTADOS:
Six eyes of five female patients were included. Mean age was 39±14y/o; mean disease duration was 32±19 mo. Two eyes had juxtafoveal CNV and four eyes had extrafoveal CNV. At CNV diagnosis, no patient had active disease; three patients were under immunosuppression. All patients received six IV bevacizumab injections and needed immunosuppression increment during the follow-up. CFT and IRF diminished but IRF persisted in all eyes. VA improved in 3 eyes, VA loss was not observed in any case.

CONCLUSÕES:
Partial improvement was observed in VKHD CNV with monthly IV bevacizumab injections combined with systemic immunosuppressants. Indeed, IRF persisted in all eyes at 6 months-endpoint denoting the aggressive nature of CNV in VKHD.

Realização Realização - CBO
Organização/Comercialização Secretaria Executiva - ASSESSOR Secretaria Executiva - MAIS EVENTOS
Agência Oficial Agência de Viagens - Luck Viajens
Agência Web Agência Web - Inteligência Web